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Serum total renin is increased before microalbuminuria in diabetes.
Serum prorenin is increased in patients with insulin-dependent diabetes
mellitus (IDDM) with microvascular complications. The present longitu-
dinal study investigated whether increases in serum total renin concentra-
tion (TRC, active+prorenin) can predict the development of microalbu-
minuria in IDDM patients over a 10 year period. TRC and albumin
excretion rates (AER) were determined in 78 IDDM patients who were
followed longitudinally for 10.4 0.2 (mean SE) years. Twelve patients
had progressively increasing albuminuria (progressors), and these were
compared to 66 patients in whom albuminuria did not rise (non-progres-
sors). The two groups had similar duration of diabetes, age, follow-up,
glycemic control and blood pressure at the start of the study. Serum TRC
was increased in progressors [350 (1.1) mIU/liter, geometric mean (toler-
ance factor)] compared to non-progressors [189 (1.2)1 after 5 to 10 years
duration of diabetes, and continued to rise in this group, reaching a mean
of 923 mIU/liter (normal range 131 to 170) after 20 years of diabetes.
When serial measurements of TRC and AER were compared in individual
progressors, a significant increase in TRC was apparent up to five years
before the onset of microalbuminuria. Microalbuminuria in patients with
IDDM is preceded by a substantial increase in serum TRC, suggesting that
serum TRC may predict the subsequent development of incipient ne-
phropathy.
Thirty to forty percent of all insulin-dependent diabetes melli-
tus (IDDM) patients develop diabetic nephropathy [1]. Although
repeated measurements of albumin excretion rate may indicate
the presence of diabetic nephropathy at an early stage, there
remains a need for a single test to reliably identify patients at risk
of nephropathy. Identification of at-risk patients is important
since aggressive blood sugar control may halve the incidence of
microalbuminuria in IDDM [2].
Inactive renin, or prorenin, circulates in comparatively high
levels in the blood of normal humans and represents about 90% of
the total renin in plasma [3]. Plasma prorenin, but not active
renin, is increased in diabetic patients with overt renal disease [4]
or proliferative retinopathy [5, 6]. It is unclear whether the
increase in inactive prorenin is linked temporally and possibly
causally to renal [7], retinal [8] or microvascular complications in
general [5], Most previous studies have been cross-sectional in
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nature. Given the frequent co-existence of diabetic kidney and eye
disease, it has been difficult to determine if the increase in plasma
prorenin relates primarily to the onset of the renal or the retinal
lesion. Nephropathy occurs in only a minority of IDDM subjects
[9], and may be on the decline [10, 11], whereas retinopathy can be
detected in over 90% of IDDM subjects after 20 years of diabetes
[12]. No long-term studies have been performed to determine if
the onset of the increase in prorenin is related to the development
of either microalbuminuria or retinopathy. The aim of this study
was to explore the relationship between TRC and emerging
microvascular complications within a study of the natural history
of diabetic nephropathy that included serial measurements of
glycemic control and blood pressure [13, 14]. Serial measurements
of serum total renin concentration (TRC) were performed by a
direct immunoradiometric assay (IRMA) in patients with IDDM
who were followed for a mean of 10 years.
Methods
Patients
Patients with type I diabetes who had attended the Austin
Hospital Endocrinology clinic regularly (at least 6 monthly) for a
minimum of eight years were eligible for inclusion. Of 108
patients satisfying this criterion, 30 were excluded from further
analysis because of: poor attendance (N = 3), overt nephropathy
at baseline with albumin excretion rate (AER) > 200 igImin,
(N = 2), pregnancy (N = 2), use of the oral contraceptive pill(N = 1), declining renal function without progression of AER(N = 8), albuminuria due to causes other than diabetic renal
disease including cardiac failure (N = 3), recurrent urinary tract
infections (N = 3), other known causes of renal disease (N = 4)
or intermittent albuminuria (N = 4). The classification of patients
as progressors was defined by two criteria. Firstly, microalbumin-
uria was defined as having at least two out of three consecutive
measurements of AER greater than 20 J.Lg/min, as previously
determined [15, 16]. Secondly, patients were defined as progres-
sors if there was a statistically significant positive regression of log
transformed AER versus time [14, 17]. This yielded 12 progres-
sors and 66 non-progrcssors.
To further explore the usefulness of total renin measurements
as a clinical laboratory test, the sensitivity, specificity and positive
predictive value of TRC were assessed in a larger group of
patients (N = 123). This larger cohort had a minimum follow-up
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of five years (range 5 to 20), included the 78 patients from the
above cohort and 45 additional patients, and yielded 104 nor-
moalbuminuric and 19 patients with persistent microalbuminuria
(2 out of 3 consecutive AER > 20 j.g/min) at start of the
follow-up.
Investigations were performed every six months and included:
serum total renin, plasma creatinine, glycated hemoglobin
(HbA1), midstream urine microscopy and culture and 24-hour
urine collection for measurement of AER and sodium. Blood
samples were drawn at the time of each clinical visit and the serum
was subsequently stored at —20°C. Retinopathy status was deter-
mined yearly as defined below.
Assay methods
Serum total renin represents both active renin and inactive
prorenin, with the inactive prorenin component comprising at
approximately 90% of total renin in normal subjects [3, 18]. Serum
TRC was assayed using a sensitive, direct two-site immunoradio-
metric assay [19] with epitope specific monoclonal antibodies (R
3-27-6 and R 3-36-16; Ciba-Geigy, Basel, Switzerland). In the
present study, a normal level of 149 (131—170) mIU/liter (geomet-
ric mean and 95% confidence levels) was derived from 29 healthy,
non-diabetic subjects. The stability of total renin was confirmed by
repeated measurements of the same samples over a five year
period. The interassay CV was 6.7% and the detection limit was
20 mIU/liter. In a subgroup of 53 IDDM patients, active renin was
measured by radioimmunoassay [18] (active renin, 21.5 1.1
mIU/liter; TRC, 238 11 mIU/liter). Mean active renin was
within the normal range in the IDDM patients representing 9% of
total renin. This is similar to that reported by our group in
non-diabetic subjects [18] and by others in IDDM patients [7].
Sodium and creatinine concentration were measured by an
autoanalyzer (Beckman Astra 8; Beckman Instruments, Palo Alto,
CA, USA). HbA1 (nondiabetic range 5 to 7.5%) was measured by
the thiobarbituric acid technique [20] from 1978 to 1981 and after
1981 by HPLC (BioRad, Richmond, CA, USA), preceded by a
dialysis step [13]. There was a close correlation between the two
methods (r = 0.90, N = 35, P < 0.001). AER was determined on
aliquots from 24-hour urine collections stored at —20°C. In all
24-hour urine samples, urinary creatinine was assayed to confirm
completeness of collection. Urinary albumin was measured by a
double antibody radioimmunoassay with an interassay coefficient
of variation of 10.9% [13].
Blood pressure was measured by a physician in the supine
position after five minutes of recumbency, using the disappear-
ance of the Korotkoff sounds (phase V) to determine diastolic
pressure. Antihypertensive therapy was initiated if blood pressure
was greater than 160/95 on three consecutive occasions [14]. No
patients were studied while on ACE inhibitors or calcium channel
blockers. Treatment during the study was with thiazide diuretics,
beta blockers, centrally acting antihypertensive agents such as
alpha methyldopa and vasodilators including prazosin. Diabetic
retinopathy was assessed yearly by an ophthalmologist after
pupillary dilation. In addition fundal photography and fluorescein
angiography were performed as indicated on clinical grounds.
Retinal lesions were categorized as either background or prolif-
erative retinopathy [21].
Table 1. Clinical characteristics of the non-progressors and progressors
Non-progressors(N = 66)
Progressors(N = 12) Pvalue
Age at start years 29 2
Duration at end years 16 1
Follow-up years 11 1
Sex (F/M) 24/42
SBP at start of study mm Hg 123 2
SBP at end of study mm Hg 128 2
DBP at start of study mm Hg 78 1
DBP at end of study mm Hg 77 1
Mean HbAI for study % 10.7 0.4
Urinary sodium excretion at end 159 7
mmol/24 hr
Retinopathy status at end of 47/17/2
study (N/B/P)



























All data are shown as mean SEM except for urinary albumin
excretion rate and plasma TRC which were logarithmically trans-
formed to normalize the data and are shown as geometric means
(tolerance factors). The initial and final data for blood pressure,
serum TRC, and albuminuria represent the mean of the first three
or last three data points, respectively. Cross-sectional analysis was
performed on the final data for serum TRC. Data were analyzed
by analysis of variance using the Statview program (Brainpower,
Calabasas, CA, USA). Comparisons between group means were
performed by Fisher's least significant difference method [22]. A P
value of less than 0.05 was viewed as statistically significant.
Results
The progressor and non-progressor groups had similar ages,
duration of follow-ups and duration of diabetes (Table 1). At the
start of the study, the number of patients in each duration
category was: 0 to 5 years, N = 66; 5 to 10 years, N = 5; 10 to 15
years, N = 4; > 15 years N = 3. All patients in the progressor
group were male and two thirds of the non-progressors were male.
There was no difference in blood pressure between the progres-
sors and non-progressors at the start of the study. However, at the
end of the study progressors had higher systolic and diastolic
blood pressures when compared with the non-progressors (P <
0.0003). There was also an increase in the percentage of patients
on antihypertensive therapy over the study period in the progres-
sor group compared with the non-progressors [progressors (totalN = 8): thiazides (4), beta blockers (2), prazosin (4); non
progressors (total N = 7): beta blockers (5), thiazides (3),
prazosin (3), alpha methyldopa (1)]. The mean HbAI over the
study was not different in the two groups. There was no difference
in final urinary sodium excretion between the progressors and
non-progressors. The severity of retinopathy was greater in the
progressors than the non-progressors ( 24.2, P = 0.008).
Cross-sectional analysis
The serum TRC at the end of the study was increased in
progressors when compared to non-progressors [progressors, 574
(1.2) vs. non-progressors 186 (1.1) mIU/liter, P = 0.0001]. By




















two-way ANOVA of final serum TRC, albuminuria and retinop-
athy, plasma TRC was shown to be related to albuminuria (P =
0.005) but not to retinopathy (Table 2). The final plasma TRC in
progressors did not relate to the presence of retinopathy [progres-
sors with retinopathy, 603 (1.3) mIU!liter, N = 8; progressors
without retinopathy, 521 (1.7), N = 4, NS]. There was no
correlation between final urinary sodium excretion and final
serum total renin (r = 0.086, P = 0.47). To explore the relation-
ship between TRC and albuminuria and blood pressure, a multi-
ple regression was performed. Final TRC was significantly related
to final AER (F = 20.1, P < 0.0001), but not to systolic (F = 0.03,
P = 0.86) or diastolic blood pressures (F = 0.44, P 0.51).
Due to the preponderance of males in the progressor group, a
subanalysis was performed to compare the progressors to the
male non-progressors with similar age and duration of diabetes
and healthy non-diabetic male subjects of similar age. Male
progressors had a higher final TRC than male non-progressors
[progressors, 574 (1.2) N = 12, vs. non-progressors, 210 (1.1) N =
42, mIU/liter, P = 0.001] and healthy non-diabetic male subjects
[164 (1.1) N = 15, mIU/liter, P < 0.00011.
Longitudinal analysis
Nephropathy. To further explore the relationship between se-
rum TRC and the evolution of diabetic nephropathy, serial
measurements of TRC were analyzed with respect to duration of
diabetes (Fig. 1). Serum TRC levels were indistinguishable be-
tween progressors and non-progressors within the first five years
of diabetes. The progressors had a higher TRC after five years
duration of diabetes when compared to the non-progressors (P <
0.01, Fig. 1), and this difference in TRC persisted over the study
period (P < 0.01 at +20 years duration). Furthermore, in contrast
to non-progressors in whom there was no increase in serum TRC
over 20 years of diabetes, serum TRC continued to rise in the
progressors [20+ years, 927 (1.5) mlU/liter].
When analyzed according to the onset of microalbuminuria,
serial measurements of serum TRC in the progressors were
significantly higher than the normal controls (P = 0.001) up to five
years before the onset of microalbuminuria and continued to
increase after its development (Fig. 2). Of the eight progrcssors
with TRC measurements before the development of microalbu-
minuria, seven had a geometric mean TRC level in their premi-
croalbuminuric phase that was significantly higher than the nor-
mals.
Since a rise in blood pressure is closely linked to the develop-
ment of microalbuminuria [23] and antihypertensive therapy has
—10—5 —5—0 0—5 5—10
Onset of microalbuminuria, years
Fig. 2. Serum total renin in relation to Onset of microalbuminuria. The
dotted line represents the upper limit of the normal range. P = 0.001,
< 0.0001 versus healthy non-diabetic controls.
been reported to decrease prorenin [24, 25], the effects of
antihypertensive therapy on TRC were assessed. Antihypertensive
therapy did not significantly influence TRC in the progressor
group (pre-trcatment TRC, 509 x/± 1.5 vs. post-treatment, 592
x/-t- 1.5, NS).
Retinopathy. To evaluate the relationship of TRC to retinopathy
alone, serial measurements of TRC were averaged and assessed in
a subgroup of 13 non-progressors with data available before and
after the onset of retinopathy. The geometric mean TRC was not
different to the normal population up to six years before the onset
of background retinopathy [210 (1.1) mIU/liter] and remained
unchanged after its onset [207 (1.2) mIU/liter], suggesting that
TRC was not related to the onset of retinopathy. However, a
Table 2. Cross-sectional analysis of TRC with respect to final renal and
retinal status
**
Geometric means (tolerance factors) are shown.
Two-way ANOVA, renal status, F = 11.3, P = 0.001; retinal status, F =
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Fig. 1. Serum total renin in relation to duration of diabetes. Geometric
means and tolerance factors are shown. The dotted line represents the
upper limit of the normal range. Symbols are: (•) progressors; (0)
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Table 3. Comparison of the effect of retinopathy and duration of







Short duration of diabetes at 156 (1.2) 323 (1.2) 0.009
end of study (<20 years) (N = 36) (N = 6)
Long duration of diabetes at 178 (1.1) 247 (1.2) NS
end of study (>20 years) (N = 11) (N = 12)
Geometric means (tolerance factors) are shown, as are the numbers of
patients.
contribution of retinopathy to TRC cannot be excluded, since the
final TRC in the non-progressors was modestly elevated in
patients with retinopathy [background+proliferative, 270 (1.2)
mIU/liter, N = 19] compared to the non-progressors without
retinopathy [161 (1.1), P < 0.01, N = 47; Table 2).
Because of the possibility that some of the non-progressors
could still be at risk of developing microalbuminuria, a further
analysis was performed in the non-progressors (Table 3). Nor-
moalbuminuric diabetics with a long duration of diabetes (> 20
years at the end of the study) and an expected decrease in
susceptibility to diabetic nephropathy were compared to nor-
moalbuminuric diabetics with a short duration of diabetes (< 20
years). In the longer duration normoalbuminuric patients TRC
was similar in those with and without retinopathy (Table 3). By
contrast, in the patients with a diabetes duration < 20 years, TRC
was significantly higher in those with retinopathy.
Sensitivity, specificity and predictive values
Clinical characteristics in the larger cohort with a minimum
duration of follow-up of five years were similar to those of the
original cohort. The normoalbuminuric (N = 104) and albumin-
uric (micro = 13, macro = 6) patients were similar in age
(normoalbuminuric 40 I vs. albuminuric 43 3 years), duration
of diabetes (16 1 vs. 16 2 years), duration of follow-up (9.7
0.3 vs. 9.4 0.7 years) and HbA1 (10.1 0.1 vs. 10.8 0.4%). In
the albuminuric group there was a preponderance of males (M:F
17:2) compared to the normoalbuminuric group (42:62, p = 0.03)
and systolic blood pressure was higher (P = 0.01). A serum TRC
of 270 mIU/liter was derived from a Receiver Operating Curve
[151 as a sensitive marker of persistent microalbuminuria (sensi-
tivity = 87%), but was not highly specific (62%). Although 17 of
19 albuminuric subjects had a raised TRC, TRC was also elevated
in 26 of 104 normoalbuminuric subjects. A serum TRC less than
270 mIU/liter indicated a high likelihood that the patient would
not develop microalbuminuria (negative predictive value =97%).
However, an elevated serum TRC did not give a high positive
predictive value (25%) for the subsequent development of mi-
croalbuminuria.
Discussion
The present study shows that in patients with IDDM elevated
serum total renin is more closely associated with microalbumin-
uria than with retinopathy. This finding was consistent for both
longitudinal and cross-sectional analyses. Furthermore, serial
measurements of TRC before and after the development of
microalbuminuria showed that TRC levels were increascd above
the normal range up to five years before the onset of persistent
microalbuminuria. In contrast, TRC remained stable and within
the normal range in patients who had no evidence of microalbu-
minuria during a mean follow-up of 10 years and did not change
with onset of diabetic retinopathy in this subgroup. The present
study provides further evidence that increases in prorenin are
linked to incipient nephropathy as suggested by cross-sectional
studies [7, 261. In contrast, Franken et at have suggested that
increased prorenin levels are associated with retinopathy rather
than microalbuminuria and that this association appears to be
more important in proliferative retinopathy [8]. In the present
study the small number of patients with proliferative retinopathy
was too small to determine the exact relationship of proliferative
retinopathy to serum TRC.
In this study, TRC was assayed by a sensitive, validated
immunoradiometric assay which measures both active refill and
inactive prorenin [19]. Active renin comprises approximately 10%
of TRC in normal individuals [3, 18] and in cohorts of IDDM
subjects [4, 7], and in established diabetes the proportion of
prorenin is even higher, rising to 96% of total renin [27]. Type I
diabetic patients with overt nephropathy are reported to have low
active renin despite the presence of hypertension, indicating that
the hypertension is not renin dependent [28]. A previous report
has suggested that certain antihypertensive drugs may influence
plasma prorenin concentrations [29]. Luetscher, Kraemer and
Wilson suggested that ACE inhibitors may increase plasma pro-
renin measurements, and for this reason patients on ACE inhib-
itors were excluded from this study [24]. In the present study there
was no significant effect of other antihypertensive drugs on TRC
levels. The direct measurement of total renin concentration
utilizing monoclonal antibodies was performed previously by
Amemiya et al [26]. They found significant differences between
normo-, micro- and macroalbuminuric IDDM patients, with levels
of TRC similar to the present values.
Activation of prorenin by limited proteolysis has often been
used to determine total renin from which inactive prorenin can be
derived; however, problems with this method include destruction
of renin, incomplete activation and changes in renin substrate
levels [3]. Furthermore, the derivation of prorenin introduces at
least twice the error compared with the direct TRC determina-
tion. The present assay, in contrast to enzyme activation methods,
can be more readily standardized, is less time-consuming and is
appropriate to clinical laboratories. This assay, including mono-
clonal antibodies for active renin, is now available commercially.
Daneman et al have suggested that the increase in plasma TRC
may be partly genetic in origin because non-diabetic siblings of
microalbuminuric IDDM patients had slightly higher TRC than
siblings from normoalbuminuric type I diabetic patients [7}.
However, the present findings do not support a genetic contribu-
tion since increases in TRC were not present at the time of
diagnosis of diabetes and were linked closely to the development
of albuminuria. Furthermore, TRC levels were indistinguishable
between progressors and non-progressors at the onset of diabetes.
However, these findings do not exclude the likelihood that
susceptibility to diabetic nephropathy per se involves genetic
factors [30].
The major findings of the present study are that the rise in TRC
preceded the onset of microalbuminuria in 13 of 15 patients with
IDDM and that the increase in TRC was independent of the
presence of retinopathy. This strengthens the use of TRC as a
marker of susceptibility to diabetic nephropathy [7, 24]. Franken
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et a! calculated that a plasma prorenin level of 225 mU/liter had
a sensitivity of 0.84 and a specificity of 0.82 for detecting the
presence of microalbuminuria based on 164 IDDM patients [6J. A
similar sensitivity for a TRC level of 270 mIU/liter in 123 patients
for detecting microalbuminuria has been observed in the present
study. This study also showed a high negative predictive value of
97%, suggesting that if a patient has a normal TRC value there is
very little likelihood of that patient developing microalbuminuria
within the next few years. The earliest predictor of overt diabetic
nephropathy is currently microalbuminuria which has a predictive
value of 80% [31]. Although microalbuminuria was originally
described as a predictor of diabetic renal disease it is now
considered part of the disease process, leading to the term
"incipient nephropathy" [321. A recent longitudinal study empha-
sized the threshold level of mieroalbuminuria as being arbitrary,
since individuals who progressed had increases in AER even
within the normoalbuminuric range [141. In histological studies
evaluating renal structure, relatively advanced renal lesions have
been observed in microalbuminurie IDDM [331. Whether the rise
in TRC can then be considered solely as a predictor of diabetic
microvascular complications, or whether the increase in TRC is a
result of early microvascular damage, remains to be determined.
Studies are required in which detailed histomorphometrie mea-
surements are performed in renal biopsies from IDDM subjects
before the development of microalbuminuria to determine if
these early rises in TRC are linked to a renal structural lesion.
Several other groups have reported elevated prorenin levels in
microalbuminuric diabetic subjects [7, 8, 26, 34]. High plasma
prorenin concentrations in diabetic patients were first described
by Day, Luetseher and Gonzales In the study by Wilson and
Luetscher, elevated plasma prorenin levels were shown to precede
the development of overt renal disease and retinopathy in ado-
lescents [5]. However, they were not able to separate the devel-
opment of renal or retinal disease in individual patients possibly
due to a follow-up of only 6 to 39 months compared with the
present 11 years. Nevertheless, their findings clearly indicated that
increased prorenin levels predict overt diabetic complications.
The present study extends the findings of Wilson and Luetscher by
associating an increase in TRC with an earlier phase of diabetic
mierovascular disease. Serial measurements of TRC allowed the
increase in TRC to be documented before the onset of microalbu-
minuria.
Serum TRC continued to rise once microalbuminuria appeared
but in the non-progressors the mean TRC remained normal
despite some individuals developing retinopathy. This leads us to
hypothesize that TRC is more closely linked to diabetic nephrop-
athy than retinopathy. Within the non-progressors there was a
tendency for TRC to he higher in patients with retinopathy, and
therefore we cannot totally discount the importance of the
association of retinopathy and increased TRC. Indeed, retinopa-
thy has been shown to he closely associated with microalbumin-
uria [36] and it is possible that the modest increase in TRC in
normoalbuminuric patients with retinopathy represents individu-
als who will ultimately develop diabetic ncphropathy. Such a
possibility is suggested by our finding that, in normoalbuminuric
patients with diabetes of less than 20 years duration, the presence
of retinopathy was associated with increased TRC. By contrast, in
individuals with a longer duration of diabetes (> 20 years) and
presumed lower susceptibility to develop microalbuminuria [37],
TRC was similar in those with and without retinopathy.
The underlying explanation for increased prorenin in the
absence of increased active renin remains controversial, but is
believed to reflect a defect in intracellular processing of renin with
an increase in the constitutive release of prorenin from the kidney
and possibly other tissues which have the capacity to express
renin. In Sprague-Dawley rats renin mRNA and protein have
been detected in adrenal, gonad, thymus, intestine, pituitary, brain
and retina [381. In humans, Franken et al have performed renal
artery and vein sampling in diabetic patients with high plasma
prorenin and have shown that prorenin is not significantly in-
creased in the renal vein, suggesting that the increase in circulat-
ing TRC in diabetes is unlikely to originate solely from the kidney
[8]. Danser et at have documented increased prorenin in ocular
vitreous fluid of patients with diabetic retinopathy [391 that could
originate from the retinal Muller cells [401. However, the retinal
content of renin is low and is unlikely to be a significant source of
prorenirl in blood. The role of extrarenal sites as an origin for
renin is further supported by evidence of detectable levels of
prorenin in anephric patients [41]. It is possible therefore, that in
diabetes the increase in prorenin reflects a generalized alteration
in the control of secretion and processing. Cathepsin B has been
identified as a candidate renin-processing enzyme co-localized to
renin-containing secretory granules in human renal juxtaglomer-
ular cells [421 and this enzyme has been shown to be decreased in
the kidney in experimental diabetes mellitus [43].
Although the present data are suggestive of a role for TRC in
the prediction of diabetic renal disease, one cannot at this stage
advocate this assay for mass screening of IDDM patients. Further
studies in larger cohorts of IDDM subjects followed for a longer
period of time are required. In addition, a formal cost benefit
analysis of TRC as a screening procedure would be necessary. If
TRC is confirmed as a consistent and early marker of diabetic
nephropathy, it would allow such diabetic patients to be targeted
for more aggressive treatment, such as strict glycemic control [21
or the use of drugs with renoprotective properties such as ACE
inhibitors [44].
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